Effect of Fluticasone Propionate Combined with Montelukast Sodium in the Treatment of Children with Cough Variant Asthma and Its Effects on Airway Inflammation and Lung Function in Children
Objective To investigate the effect of fluticasone propionate combined with montelukast sodium in the treatment of children with cough variant asthma (CVA) and its effects on their airway inflammation and lung function. Methods A total of 76 children with CVA admitted to Yankuang Xinlicheng General Hospital from August 2021 to August 2023 were selected as the research objects and were divided into a control group and an observation group according to random number table method,with 38 cases in each group. Both groups received conventional treatment. On this basis,the control group was treated with fluticasone propionate inhalation aerosol,and the observation group was treated with fluticasone propionate inhalation aerosol combined with montelukast sodium tablets. The indexes of airway inflammation,lung function,airway remodeling and adverse reactions were compared between the two groups. Results After treatment,the levels of interleukin-4 and eosinophils in the observation group were (110.65±15.43)ng/mL and (2.90±0.41)％,respectively,which were lower than (145.82±26.74)ng/mL,(14.59±0.88)％ in the control group,and the level of interleukin-10 was (19.56±2.44)ng/mL,which was higher than (15.37±2.10)ng/mL in the control group,the differences between the groups were statistically significant (P<0.05);the peak expiratory flow,forced vital capacity and forced expiratory volume in one second of the observation group were higher than those of the control group,and the differences between the groups were statistically significant (P<0.05);the airway lumen area and total airway area in the observation group were greater than those in the control group,and the airway wall area was smaller than that in the control group,and the differences between the groups were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Montelukast sodium combined with fluticasone propionate can inhibit airway remodeling,relieve airway inflammation and improve lung function in children with CVA,and the incidence of adverse reactions is low,which is worthy of clinical promotion.
Cough variant asthmaChildrenFluticasone propionateMontelukast sodiumAirway inflammationLung function
NETL
NSTL
万方数据
